NCT03329664

Autologous Killer Cell Therapy in Colon Cancer Patients

Safety and Efficacy of ex Vivo Activated and Expanded Autologous Cytokine-induced Killer Cells for Colon Cancer Patients

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Sabz Biomedicals · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the safety and efficacy of activated and expanded autologous cytokine-killer cells in controlling disease recurrence in colon cancer patients with liver metastasis. 20 patients with confirmed stage IV colon carcinoma with metastasis will be assigned into two groups. Patients in both groups will receive the same therapeutic regimen as usual. Patients in one group additionally will be treated with a single infusion of autologous killer cells that had been previously prepared from peripheral blood.

Conditions

• Colon Cancer Stage IV

Interventions

Type	Name	Description
BIOLOGICAL	Cytokine-induced killer cell	Immune-cell therapy with CIK cells
OTHER	Chemotherapy AND/OR Radiation Therapy	Routine treatments for colon cancer patients according to their stage

Timeline

• Start date: 2020-02-09
• Primary completion: 2021-09-01
• Completion: 2022-01-01
• First posted: 2017-11-06
• Last updated: 2021-03-15

Locations

1 site across 1 country: Iran